Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.
806-ADC
89Zr-ch806
EGFR
malignant mesothelioma
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
02 Oct 2020
02 Oct 2020
Historique:
received:
07
09
2020
revised:
26
09
2020
accepted:
28
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
8
10
2020
Statut:
epublish
Résumé
Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a tumor-selective epitope. MAb806-derived antibody drug conjugates (ADCs), ABT-414, ABBV-221 and ABBV-322, may represent a novel therapeutic strategy in MM. EGFR and mAb806 epitope expressions in mesothelioma cell lines were evaluated using an array of binding assays, and the in vitro cell effects of ABT-414 and ABBV-322 were determined. In vivo therapy studies were conducted in mesothelioma xenograft and patient-derived xenograft (PDX) tumor models. We also performed biodistribution and imaging studies to allow the quantitative targeting of MM by mAb806 using a
Identifiants
pubmed: 33023139
pii: ph13100289
doi: 10.3390/ph13100289
pmc: PMC7601847
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Cancer Council Victoria
ID : 139777
Références
J Clin Oncol. 2007 Jun 10;25(17):2406-13
pubmed: 17557954
J Nucl Med. 2010 Aug;51(8):1293-300
pubmed: 20660376
Int J Oncol. 2012 Nov;41(5):1610-8
pubmed: 22922885
Lung Cancer. 2006 Feb;51(2):207-15
pubmed: 16384623
Cancer Treat Rev. 2011 Nov;37(7):533-42
pubmed: 21183281
Br J Cancer. 1999 Dec;81(8):1344-50
pubmed: 10604731
Mol Cancer Ther. 2020 Oct;19(10):2117-2125
pubmed: 32847977
J Immunol Methods. 1984 Aug 3;72(1):77-89
pubmed: 6086763
Mol Cancer Ther. 2018 Apr;17(4):795-805
pubmed: 29483208
Mol Biol Med. 1983 Dec;1(5):511-29
pubmed: 6094961
Theranostics. 2018 Jul 30;8(15):4199-4209
pubmed: 30128047
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
pubmed: 2359136
Clin Cancer Res. 2014 Dec 1;20(23):5927-36
pubmed: 25231400
Mol Cancer Ther. 2015 May;14(5):1141-51
pubmed: 25731184
Clin Cancer Res. 2005 Mar 15;11(6):2300-4
pubmed: 15788680
J Cancer Res Clin Oncol. 2008 Oct;134(10):1105-11
pubmed: 18392851
Br J Cancer. 2005 Mar 28;92(6):1069-77
pubmed: 15770208
Med J Aust. 2011 Sep 5;195(5):271-4
pubmed: 21895596
J Thorac Oncol. 2016 Jun;11(6):e78-80
pubmed: 27211582
J Surg Oncol. 2011 Nov 1;104(6):701-5
pubmed: 21437912
Cancer. 2008 Aug 15;113(4):808-14
pubmed: 18543326
Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31
pubmed: 8052651
Mol Imaging. 2013 Jan-Feb;12(1):17-27
pubmed: 23348788
Invest New Drugs. 2015 Jun;33(3):671-8
pubmed: 25895099
Hum Gene Ther. 2008 Aug;19(8):774-82
pubmed: 18754710
Molecules. 2018 Nov 29;23(12):
pubmed: 30501113
Cancer. 2018 May 15;124(10):2174-2183
pubmed: 29533458
J Clin Oncol. 2020 Jun 1;38(16):1824-1835
pubmed: 32213105
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6
pubmed: 17360479
Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217
pubmed: 29075855
Cancer Res. 2001 Jun 1;61(11):4474-82
pubmed: 11389078
Nat Rev Cancer. 2015 May;15(5):311-6
pubmed: 25907221
Bioconjug Chem. 2013 Jul 17;24(7):1256-63
pubmed: 23808985
BMC Cancer. 2006 May 17;6:130
pubmed: 16704740
Neuro Oncol. 2019 Jan 1;21(1):106-114
pubmed: 29982805
J Nucl Med. 2016 Jun;57(6):974-80
pubmed: 26940768
Cancer Res. 2012 Jun 15;72(12):2924-30
pubmed: 22659454
Invest New Drugs. 2020 Oct;38(5):1483-1494
pubmed: 32189093
J Nucl Med. 2009 Jun;50(6):974-81
pubmed: 19443585
PLoS One. 2011 Mar 25;6(3):e18198
pubmed: 21464917
Clin Cancer Res. 2017 Feb 15;23(4):1060-1067
pubmed: 27683181
J Clin Oncol. 2003 Oct 15;21(20):3798-807
pubmed: 12953099
J Biol Chem. 2004 Jul 16;279(29):30375-84
pubmed: 15075331
Mol Cancer Ther. 2016 Apr;15(4):661-9
pubmed: 26846818